Option chain shows key data for Terumo's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Terumo.

Terumo (OTC:TRUMY) Stock, Option Chain

Terumo

Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.

Earnings

Large Cap

News

Markets

Analyst Ratings

Tech

Trading Ideas

TRUMY

Most of us have heard the dictum &#34;the trend is your friend.&#34; And this is undeniably the key to success when it comes to short-term investing or trading. But it isn&#39;t easy to ensure the sustainability of a trend and profit from it.

Terumo Is a Great Choice for &#39;Trend&#39; Investors, Here&#39;s Why

NARI

Analyst Color

Equities

Health Care

Price Target

Initiation

General

TRUMF

Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.

Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

Biotech

Penny Stocks

STSS

The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices.

Terumo Corp

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Terumo Gaining Share In Growth Markets, But Consistency Still A Question

Terumo Corporation (TRUMF) Q1 2025 Earnings Call Transcript

ClearBridge International Growth EAFE Strategy Q3 2024 Commentary

ClearBridge International Growth ADR Strategy Q3 2024 Commentary

ClearBridge International Growth ACWI Ex-US Strategy Q3 2024 Commentary

Terumo Corporation 2025 Q2 - Results - Earnings Call Presentation

Terumo Corporation (TRUMF) Q2 2025 Earnings Call Transcript

AAGIY

AAIGF

ANFGF

AORT

ARGNF

ARGX

ASCCF

ASCCY

ASML

ASMLF

CFCV

CMPGF

CMPGY

CMSQF

CMSQY

CMXHF

CPNG

CSLLY

DAIUF

DANOY

DFKCY

ESLOF

ESLOY

GPDNF

GVDBF

GVDNY

HLNCF

HOCPF

HOCPY

HXGBF

HXGBY

HXSCF

ICLR

INFR

LDNXF

LGRDY

LGRVF

LNSTY

LNVGF

LNVGY

LRGE

MDNDF

MNDY

NONOF

NPXYY

NSRGF

NSRGY

PRYMF

PRYMY

PUGBY

PUIGF

RKLIF

SAPGF

SMCAY

SMECF

SPOT

SSDOF

SSDOY

TKOMF

TKOMY

TOELF

TOELY

TYNPF

YLDE

Press Releases

Terumo Medical Corporation's New AZUR HydroPack™ Peripheral Coil System Provides a Soft-Packing, Long-Lasting Solution to Embolotherapy

FDA Clears the Individualized Nomogram for Rika Plasma Donation System

Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView™ Monitoring System

Terumo Establishes Corporate Venture Capital "Terumo Ventures"

Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients

TYO:4543

Comments

Terumo

Terumo (TRUMY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga